Tirzepatide and Kidney Stones: What the Evidence Actually Shows

Does tirzepatide directly cause kidney stones?

There is a common assumption that because GLP-1 medicines affect how the kidneys handle certain substances, they must raise the risk of kidney stones. The evidence does not support that conclusion for tirzepatide specifically. Kidney stones were not reported as an adverse event in the SURMOUNT-1 trial, and the NHS medicines page for tirzepatide does not include them in its side-effect listings. The UK Summary of Product Characteristics, available on the electronic Medicines Compendium, similarly makes no mention of nephrolithiasis.

Where kidney stones do become relevant is through a secondary mechanism: dehydration. Nausea and vomiting are among the most frequently reported side effects of tirzepatide, particularly in the first few weeks of treatment and after each dose increase. Fluid loss from repeated GI symptoms concentrates urine, and concentrated urine is precisely the environment in which stones form. This is not unique to tirzepatide (it is a risk with any medicine that causes significant GI upset) but it is worth taking seriously if you already know your kidneys are prone to stone formation. You can read more about whether tirzepatide causes kidney stones and how kidney function fits into the broader picture on our dedicated overview page.

The short answer: tirzepatide does not appear to cause kidney stones directly. The indirect pathway through dehydration is real, manageable, and something to discuss with your prescriber.

What should you tell your prescriber if you have a stone history?

Disclosure matters here more than with many other conditions. A history of kidney stones tells a clinician several things at once: how your kidneys respond to changes in hydration and urine chemistry, whether you have underlying metabolic factors (high uric acid, hypercalciuria, cystinuria) that need accounting for, and whether you are already taking medicines (potassium citrate, thiazide diuretics, allopurinol) that interact with anything in your treatment plan.

None of this is a barrier by default. Many people with a stone history take GLP-1 medicines safely. What it does mean is that your prescriber needs the full picture: when your last stone episode was, what type of stone it was if you know, how often they recur, and whether your kidneys have any lasting structural change. Our clinical team reviews every consultation personally before anything is prescribed; your stone history will be read, not skimmed.

If your stone disease is actively being managed by a urologist or nephrologist, loop them in before starting any new treatment. That is not a deflection, it is the right sequence. A question our prescribers hear regularly is whether previous stones disqualify someone from treatment entirely; almost always the answer is no, but the decision belongs to a clinician who knows your full case.

For a broader look at whether Mounjaro can cause kidney stones and how those concerns connect to practical prescribing decisions, that page covers the questions in more detail.

How to protect your kidneys during tirzepatide treatment

The most practical thing anyone with a stone history can do on tirzepatide is drink enough water, not heroic amounts, but consistent, steady fluid intake across the day. The NHS recommends around 1.5–2 litres for most adults in normal conditions; if GI side effects are making it hard to keep fluids down, that is exactly the moment to act rather than push through.

Signs that dehydration may be affecting your kidneys include a marked drop in how often you urinate, very dark urine, dizziness, and feeling more unwell than nausea alone would explain. Seek medical attention if you develop severe pain in your side or lower back, notice blood in your urine, or find urination becomes painful or difficult. These are not expected side effects of tirzepatide and should be assessed promptly.

The MHRA's Yellow Card scheme allows patients to report any unexpected symptoms they believe may be linked to a medicine (including new kidney symptoms) and that reporting genuinely helps the MHRA monitor real-world safety signals over time.

Lifestyle factors that reduce stone risk (good hydration, moderate salt, adequate calcium from food rather than supplements, limiting high-oxalate foods if your stones are oxalate-type) remain relevant alongside treatment. If you are also wondering whether you can drink alcohol on Mounjaro, that is worth factoring into your weight-loss plan as well.

Who should talk to a specialist before starting?

Most people with a past kidney stone episode can discuss tirzepatide with a prescriber through the normal consultation process. The situations that warrant specialist input first are more specific: stones that are actively recurring, significant structural kidney damage on imaging, single-kidney status, known metabolic conditions driving stone formation, or any current symptoms that have not been fully investigated. If you fall into one of those groups, a nephrologist or urologist should be part of the conversation before you start a new medicine, and our page on how tirzepatide interacts with kidney function more broadly is a useful place to read up before that appointment.

Pregnancy is an absolute contraindication for tirzepatide regardless of kidney history, the medicine is not recommended during pregnancy, while breastfeeding, or in the months before trying to conceive. Under-18s are also outside the licensed indication. These boundaries are set in the SmPC and are not a matter of clinical discretion.

For those who are clinically suitable, the practical question of whether mounjaro is appropriate with a kidney-stone history comes down to individual assessment, and our page on Mounjaro and kidney stones explores the specific considerations in more detail. If you are ready to have that conversation, a prescriber at nume reviews consultations the same working day. Start with the free consultation and bring your full medical history, stone episodes included.